Pliant Therapeutics Inc
PLRX1.430USD
-0.060-4.03%
收盘 09/19, 16:00（美东）报价延迟15分钟
87.78M总市值
亏损市盈率 TTM
关于 Pliant Therapeutics Inc 公司
Pliant Therapeutics, Inc. 是一家临床阶段的生物技术公司。该公司专注于发现和开发用于治疗纤维化和相关疾病的疗法。其主要候选产品 bexotegrast (PLN-74809) 是一种口服小分子 αvß6 和 αvß1 整合素双重选择性抑制剂，正在开发用于治疗特发性肺纤维化 (IPF) 和原发性硬化性胆管炎 (PSC) 的主要适应症。该公司已启动 BEACON-IPF，这是一项针对 IPF 的 bexotegrast 的 2b 期试验。它还开发了 PLN-1474，一种用于治疗伴有肝纤维化的非酒精性脂肪性肝炎 (NASH) 的小分子选择性抑制剂。该公司已启动第三个临床项目 PLN-101095 的 1 期研究，PLN-101095 是一种小分子、αvß8 和 αvß1 整合素的双选择性抑制剂，正在开发用于治疗实体肿瘤。该公司有一个临床前项目 PLN-101325，针对肌肉营养不良症。
公司简介
公司代码PLRX
公司名称Pliant Therapeutics Inc
上市日期Jun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
员工数量171
证券类型Ordinary Share
年结日Jun 03
公司地址331 Oyster Point Boulevard
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16504816770
网址https://pliantrx.com/
公司代码PLRX
上市日期Jun 03, 2020
CEODr. Bernard J. Coulie, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Dr. Delphine Imbert, Ph.D.
Dr. Delphine Imbert, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
705.63K
-8.97%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-68.53%
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月10日 周三
更新时间: 9月10日 周三
持股股东
股东类型
持股股东
持股股东
占比
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
6.43%
The Vanguard Group, Inc.
4.89%
Blue Owl Capital Holdings LP
4.84%
UBS Financial Services, Inc.
4.31%
其他
69.76%
持股股东
持股股东
占比
Tang Capital Management, LLC
9.77%
Deep Track Capital LP
6.43%
The Vanguard Group, Inc.
4.89%
Blue Owl Capital Holdings LP
4.84%
UBS Financial Services, Inc.
4.31%
其他
69.76%
股东类型
持股股东
占比
Hedge Fund
34.96%
Investment Advisor
23.08%
Investment Advisor/Hedge Fund
13.52%
Research Firm
8.99%
Venture Capital
4.17%
Individual Investor
3.04%
Family Office
0.87%
Pension Fund
0.05%
Private Equity
0.04%
其他
11.28%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
374
62.63M
102.02%
-15.09M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
2023Q2
347
62.06M
104.99%
-496.00K
2023Q1
337
60.53M
102.92%
+8.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tang Capital Management, LLC
6.00M
9.77%
+6.00M
--
Mar 31, 2025
Deep Track Capital LP
5.40M
8.8%
-572.58K
-9.59%
Mar 31, 2025
The Vanguard Group, Inc.
3.33M
5.42%
+105.82K
+3.29%
Mar 31, 2025
Blue Owl Capital Holdings LP
2.97M
4.84%
+200.00K
+7.22%
Mar 31, 2025
UBS Financial Services, Inc.
2.65M
4.31%
+2.02M
+321.08%
Mar 31, 2025
Woodline Partners LP
2.51M
4.1%
+2.39M
+1875.01%
Mar 31, 2025
Madison Avenue Partners LP
1.68M
2.73%
+1.68M
--
Mar 31, 2025
Third Rock Ventures, LLC
2.13M
3.47%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
1.03M
1.67%
+510.82K
+98.79%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
DFA Dimensional US Core Equity Market ETF
占比0%
Invesco RAFI US 1500 Small-Mid ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
